olivLaw · US equity research
agilon health, inc. AGL
Services-Misc Health & Allied Services, NEC · SIC 8090 · Vertical: Services-Misc Health & Allied Services, NEC (SIC 8090)
agilon health empowers primary care physicians in their communities to manage the total healthcare needs of Medicare Advantage patients through risk-bearing capitation arrangements. The company is working through losses and a shifting membership base, but in the second quarter of 2026 it raised its full-year outlook, making the trajectory of medical margin and Adjusted EBITDA worth watching closely.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, agilon health, inc. (AGL) stock was 96.23 USD (+9.61% on the day), with market capitalisation 1.6 bn USD, P/E 16.5 on diluted EPS of 5.83 USD over the last 12 months, beta 0.88, 52-week range 7.91–129.84 USD. Latest reported quarter (Q3 2026): revenue of 1.5 bn USD (+5.9% YoY), net income of 34.9 m USD, diluted EPS 1.97 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 63.8
- strong (55–70)
- Bollinger (20, 2)
- 81.94 – 94.51
- above the upper band · %B 1.14 · band width 14.2%
- SMA 50 / 200
- 87.55 / 65.97
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.87 / 0.45
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +14.2% | −1.1% | +15.3 pp | — |
| 3 months | −10.8% | −0.5% | −10.3 pp | — |
| 6 months | +245.5% | +4.4% | +241.1 pp | — |
| Year to date | +458.7% | +12.3% | +446.3 pp | — |
| 1 year | +431.7% | +13.5% | +418.1 pp | +14.1% |
| 3 years | −73.7% | +76.4% | −150.2 pp | −5.2% |
| 5 years | −84.6% | +63.7% | −148.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 bn | 1.5 bn | 1.4 bn | 1.4 bn | 1.6 bn | 1.4 bn | 1.5 bn | 1.5 bn |
| Operating income | -108.1 m | -22.1 m | -116.0 m | -131.3 m | -193.8 m | 4.0 m | 11.8 m | 24.1 m |
| Depreciation & amortisation | 6.5 m | 6.9 m | 7.3 m | 7.4 m | 7.0 m | 6.8 m | 6.9 m | 6.7 m |
| Interest expense | 1.6 m | 1.5 m | 1.6 m | 1.8 m | 1.7 m | 1.8 m | 1.6 m | 1.7 m |
| Pre-tax income | -104.7 m | -1.7 m | -104.3 m | -110.5 m | -187.6 m | 29.9 m | 17.6 m | 38.9 m |
| Income tax | 1.8 m | 196.0 k | 62.0 k | -331.0 k | 1.3 m | 28.0 k | -375.0 k | 4.0 m |
| Net income | -105.8 m | 12.1 m | -104.4 m | -110.2 m | -188.9 m | 48.9 m | 18.0 m | 34.9 m |
| Diluted EPS | — | 0.73 | -6.31 | -6.65 | -0.12 ≈ | 2.94 | 1.04 | 1.97 |
| Operating cash flow | 16.4 m | -32.0 m | -35.1 m ≈ | -18.2 m ≈ | -20.5 m | 23.7 m | -57.3 m ≈ | 49.9 m ≈ |
| Capex | 3.3 m | 3.8 m | 3.3 m ≈ | 3.2 m ≈ | 3.0 m | 3.1 m | 3.4 m ≈ | 3.3 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 100 percentile of its own 1-quarter history (min 13.6, median 13.6, max 13.6; quarters with earnings only).
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 794.4 m | 1.2 bn | 1.5 bn | 2.4 bn | 4.3 bn | 6.1 bn | 5.9 bn |
| Revenue YoY | unavailable | +53.4% | +24.9% | +57.0% | +80.7% | +40.4% | −2.1% |
| Net income | -282.6 m | -60.1 m | -406.5 m | -106.6 m | -262.6 m | -260.2 m | -391.3 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -35.6% | -4.9% | -26.7% | -4.5% | -6.1% | -4.3% | -6.6% |
| Free cash flow | -106.8 m | -55.0 m | -154.7 m | -146.2 m | -172.0 m | -71.0 m | -119.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 173.7 m USD
- Financial debt
- 35.0 m USD
- Net debt
- -138.7 m USD
- Equity
- 126.7 m USD
- Total assets
- 1.3 bn USD
- Debt / equity
- 0.28x
- Current ratio
- 1.02x
- ROE
- -131.0%
- ROA
- -26.0%
- FCF margin
- -2.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.2 bn | 1.5 bn | 2.4 bn | 4.3 bn | 6.1 bn | 5.9 bn | SEC (XBRL)· 25 Feb 2026verified |
| Operating income | -56.7 m | -372.2 m | -105.4 m | -232.1 m | -292.1 m | -463.2 m | SEC (XBRL)· 25 Feb 2026verified |
| Depreciation & amortisation | 14.1 m | 14.7 m | 13.8 m | 20.2 m | 24.5 m | 28.6 m | SEC (XBRL)· 25 Feb 2026verified |
| EBITDA | -42.6 m ≈ | -357.6 m ≈ | -91.6 m ≈ | -212.0 m ≈ | -267.7 m ≈ | -434.6 m ≈ | SEC (XBRL)· 25 Feb 2026derived |
| Interest expense | 8.1 m | 6.1 m | 4.5 m | 6.7 m | 6.2 m | 6.6 m | SEC (XBRL)· 25 Feb 2026verified |
| Pre-tax income | -62.3 m | -383.0 m | -90.7 m | -194.5 m | -248.8 m | -404.1 m | SEC (XBRL)· 25 Feb 2026verified |
| Income tax | 865.0 k | 886.0 k | 1.6 m | 791.0 k | 1.5 m | 1.3 m | SEC (XBRL)· 25 Feb 2026verified |
| Net income | -60.1 m | -406.5 m | -106.6 m | -262.6 m | -260.2 m | -391.3 m | SEC (XBRL)· 25 Feb 2026verified |
| Weighted average diluted shares | 323.5 m | 372.9 m | 408.2 m | 408.9 m | 411.0 m | 414.0 m | SEC (XBRL)· 25 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 106.8 m | 1.0 bn | 465.3 m | 107.6 m | 188.2 m | 173.7 m | SEC (XBRL)· 25 Feb 2026verified |
| Current assets | 294.2 m | 1.4 bn | 1.5 bn | 1.5 bn | 1.5 bn | 1.1 bn | SEC (XBRL)· 25 Feb 2026verified |
| Property, plant & equipment, net | 6.5 m | 9.2 m | 19.9 m | 27.6 m | 28.2 m | 25.4 m | SEC (XBRL)· 25 Feb 2026verified |
| Goodwill | 41.5 m | 41.5 m | 2.5 m | 24.1 m | 24.1 m | 0 | SEC (XBRL)· 25 Feb 2026verified |
| Intangibles (excl. goodwill) | 60.5 m | 55.4 m | 18.4 m | 63.8 m | 72.8 m | 65.7 m | SEC (XBRL)· 25 Feb 2026verified |
| Total assets | 446.4 m | 1.6 bn | 1.7 bn | 1.7 bn | 1.7 bn | 1.3 bn | SEC (XBRL)· 25 Feb 2026verified |
| Accounts payable | 97.2 m | 112.9 m | 177.4 m | 239.4 m | 220.3 m | 127.5 m | SEC (XBRL)· 25 Feb 2026verified |
| Short-term debt | 3.0 m | 5.0 m | 5.0 m | 6.3 m | 0 | 19.2 m | SEC (XBRL)· 25 Feb 2026verified |
| Long-term debt | 64.7 m | 43.4 m | 38.5 m | 32.3 m | 34.9 m | 15.8 m | SEC (XBRL)· 25 Feb 2026verified |
| Current liabilities | 266.8 m | 357.0 m | 535.1 m | 977.2 m | 1.2 bn | 1.1 bn | SEC (XBRL)· 25 Feb 2026verified |
| Total liabilities | 421.6 m | 494.7 m | 656.9 m | 1.1 bn | 1.3 bn | 1.1 bn | SEC (XBRL)· 25 Feb 2026verified |
| Equity | -284.7 m | 1.1 bn | 1.0 bn | 661.0 m | 471.0 m | 126.7 m | SEC (XBRL)· 25 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -53.2 m | -148.2 m | -130.8 m | -156.2 m | -57.8 m | -105.8 m | SEC (XBRL)· 25 Feb 2026verified |
| Capex | 1.8 m | 6.6 m | 15.4 m | 15.8 m | 13.3 m | 13.2 m | SEC (XBRL)· 25 Feb 2026verified |
| Free cash flow | -55.0 m ≈ | -154.7 m ≈ | -146.2 m ≈ | -172.0 m ≈ | -71.0 m ≈ | -119.0 m ≈ | SEC (XBRL)· 25 Feb 2026derived |
| Investing cash flow | 22.1 m | -90.5 m | -444.4 m | -44.0 m | 139.9 m | 88.6 m | SEC (XBRL)· 25 Feb 2026verified |
| Financing cash flow | 24.6 m | 1.2 bn | 28.1 m | -193.1 m | -2.6 m | -3.0 m | SEC (XBRL)· 25 Feb 2026verified |
| Share repurchases | 6.7 m | — | — | 200.0 m | — | — | SEC (XBRL)· 27 Feb 2024verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 54.2% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.6 bn USD
Key indicators
Coverage and freshness
Score by group
54% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 50.87 – 157.95 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/E50.87 – 157.95 (Mid 118.78)6 companies used · median multiple 20.4x · quartiles 8.7x – 27.1xDVA, FMS, NIVF, PGNY, SHC, VMD
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 54.2% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -84.4% | 0 (on a fixed band) | 19% |
| Net margin · Quality | -1.5% | 30 (vs peers) | 12% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 35.4% | 100 (on a fixed band) | 15% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -22.4x | 0 (on a fixed band) | 12% |
| Current ratio · Balance sheet | 1.1x | 28 (on a fixed band) | 8% |
| P/E (TTM) · Valuation | 16.5x | 50 (vs peers) | 19% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -1.1% | 0 (on a fixed band) | 15% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet11/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality11/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation28/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
agilon health, inc. (AGL). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 5.9 bn USD in 2025; YoY growth -2.1%; net margin -1.5%; ROE -29.7%.
The estimated value range is 50.87–157.95 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 118.78 USD, the price of 96.23 USD leaves a potential of 23.4% (value / price − 1) and a margin of safety of 19.0% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 54.2% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 35.4%
What contradicts it
- ROIC: -84.4%
- Net margin: -1.5%
- Interest coverage: -22.4x
- Current ratio: 1.1x
- FCF yield: -1.1%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Misc Health & Allied Services, NEC (SIC 8090) · same industry (4-digit SIC) · compared with 10 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| DVADavita Inc. | 12.1 bn | 14.2 | — | 6.5% | +6.5% | +61% / +90% |
| FMSFresenius Medical Care AG | 6.5 bn | 6.9 | 7.0% | 5.0% | +1.5% | −3% / +13% |
| SHCSotera Health Company | 4.7 bn | 27.3 | 27.0% | 14.1% | +5.7% | −6% / +20% |
| PGNYProgyny, Inc. | 2.3 bn | 32.7 | 16.2% | 6.0% | +10.4% | +14% / −12% |
| AGLagilon health, inc. | 1.6 bn | 16.5 | -29.7% | -1.5% | −2.1% | +432% / −74% |
| VMDViemed Healthcare, Inc. | 383.1 m | 26.5 | 11.0% | 5.0% | +20.5% | +46% / +30% |
| CCELCryo-Cell International, Inc. | 40.9 m | — | — | -6.2% | −1.3% | +18% / −5% |
| BRTXBiorestorative Therapies, Inc. | 38.5 m | — | -241.1% | -3,089.6% | −10.3% | +40% / −21% |
| MGRXMangoceuticals, Inc. | 4.5 m | — | -95.1% | -4,791.3% | −26.0% | −81% / −98% |
| NIVFNewgenivf Group Limited | 166.5 k | 0.2 | 77.2% | 209.0% | −13.0% | −100% / −100% |
| MCTACharming Medical Limited | — | — | -0.9% | -0.5% | −22.7% | unavailable / unavailable |
1- and 3-year price returns: for AGL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
In brief
agilon health empowers primary care physicians in their communities to manage the total healthcare needs of Medicare Advantage patients through risk-bearing capitation arrangements. The company is working through losses and a shifting membership base, but in the second quarter of 2026 it raised its full-year outlook, making the trajectory of medical margin and Adjusted EBITDA worth watching closely 13.
SWOT
Strengths
Weaknesses
Opportunities
- If the number of Medicare Advantage patients keeps growing, expansion into new geographies could add members 1.
- Better burden of illness performance and cost control could improve medical margin in the coming years 3.
- Participation in CMS ACO models could add income through unconsolidated entities 13.
Risks
- Net losses and rising expenseshigh
The company has reported net losses in recent years and expects expenses to rise, which could keep it from reaching profitability 1.
- Dependence on payorshigh
Revenue depends on a limited number of payors, and contracts have limited terms and can be terminated on certain events 1.
- Exchange listing riskhigh
The company's shares did not meet the NYSE minimum price requirement, and if a reverse stock split does not cure the deficiency, trading could be affected 1.
- Medical costs and risk estimatesmedium
Medical costs may exceed revenue, and estimates of risk adjustment and unreported claims may prove inaccurate 1.
- Regulation and auditsmedium
Payor audits, federal investigations and repayment obligations could create additional financial liabilities 1.
Investment thesis
What would need to be true (bull case)
- If the Total Care model expands and partner physicians improve performance, medical margin could keep recovering, in line with the revised guidance 3.
- Long-term partnerships and the physician network could make the company hard to replace in the communities where it operates 1.
- If demand for Medicare Advantage care grows, the company could regain members and return to revenue growth 13.
What would break the thesis
- If net losses continue and membership keeps declining, pressure on the balance sheet could increase 12.
- Dependence on a few payors and short contract terms could leave revenue exposed to policy changes 1.
- Exchange delisting risk and regulatory issues could weigh on investor confidence and access to capital 1.
What to watch
- Delivery against the revised guidance for revenue and medical marginQ3 2026
- Trend in MA membership and ACO model membershipQ3 2026
- Outcome of the reverse stock split vote2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
The business
agilon health aims to transform healthcare by empowering primary care physicians (PCPs) in the communities they serve. Its model rests on the agilon platform, long-term partnerships with anchor physician groups, typically 20 years in duration, and a network of like-minded physicians 1. The company forms risk-bearing entities (RBEs) in each local geography, which enter into monthly capitation arrangements with payors to manage the total healthcare needs of attributed patients 1. Payors receive premiums from CMS and pay agilon a defined percentage of them, and agilon shares surplus with its anchor physician groups 1.
The company was formed in 2016 and established its first anchor physician partnership in 2017 1. As of December 31, 2025, it had 28 anchor physician groups across 30 geographies 1. Substantially all revenue comes from medical services, primarily capitation 1.
The company operates essentially one business line, medical services for Medicare Advantage patients, and through its participation in CMS ACO models it also reports results from entities it does not consolidate 13. The model depends on growing physician partner capacity and maintaining profitable payor contracts 1.
Segments
Market context
The target market is Medicare Advantage patients in the United States, and value-based payment is more attractive to primary care physicians than fee-for-service payment 1. MA membership and payor budgets depend on CMS policy and annual payor bids 1.
Growth depends on how quickly physicians and health systems adopt the Total Care model, the company's ability to recruit new physicians, and payors' willingness to sign profitable contracts 13.
Trends
- Shift to the Total Care modeltailwind
Physician adoption of global capitation could open long-term revenue growth if partner physicians manage costs and quality of care well 1.
- Membership adjustmentheadwind
Membership fell in 2025 and in the first half of 2026, reflecting market exits and a more selective contracting approach, which could limit near-term growth 23.
- Medical costs and marginmixed
The raised medical margin guidance was linked to stronger burden of illness performance and favorable cost trends, and if those trends do not hold, margin could come in below the revised outlook 3.
- Pricing and regulatory riskheadwind
Changes in CMS rates and Medicare Advantage rules can alter revenue and margins, and the company relies on payors to pay claims on its behalf 1.
Competitive position
The company competes with other organizations that manage Medicare Advantage patient care, with physician networks, and with health systems building their own capitation models 1. Competition for primary care physicians and payor contracts could affect its ability to grow membership 1.
Its advantage lies in long-term partnerships with physician groups and a like-minded physician network, which can make anchor groups harder to replace 13.
- Other Medicare Advantage care organizations
Companies managing MA capitation contracts compete for the same payors and primary care physicians 1.
- Physician networks and health systems
Systems building their own Total Care models could compete with the company's physician partner groups 1.
- Payors running their own care programs
Payors may try to manage care directly, reducing room for risk-bearing entities 1.
- Other ACO participants
ACOs in the same geographies compete for fee-for-service Medicare beneficiaries 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report04 Nov 2026
- Current report04 Nov 2026Results of operations · Financial statements and exhibits
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report22 Jul 2026Departure or appointment of officers · Financial statements and exhibits
- Current report03 Jun 2026Shareholder vote
- Quarterly report06 May 2026
- Current report06 May 2026Results of operations · Financial statements and exhibits
- Current report27 Apr 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Proxy statement22 Apr 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / agilon health, inc. · 25 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / agilon health, inc. · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / agilon health, inc. · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.